Curis Revenue and Competitors
Estimated Revenue & Valuation
- Curis's estimated annual revenue is currently $15M per year.
- Curis's estimated revenue per employee is $81,522
- Curis's total funding is $69M.
Employee Data
- Curis has 184 Employees.
- Curis grew their employee count by -16% last year.
Curis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Interim VP | Reveal Email/Phone |
2 | VP, Clinical Operations | Reveal Email/Phone |
3 | VP, Medical Affairs | Reveal Email/Phone |
4 | VP Regulatory Affairs | Reveal Email/Phone |
5 | VP Portfolio Management | Reveal Email/Phone |
6 | VP - Technology Management and Intellectual Property | Reveal Email/Phone |
7 | Head Research And Development | Reveal Email/Phone |
8 | VP, Technical Operations | Reveal Email/Phone |
9 | VP, Clinical Science | Reveal Email/Phone |
10 | VP, Head Biostatistics and Data Management | Reveal Email/Phone |
Curis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Curis?
Curis, Inc. is generating therapies that regulate the pathways used by the body to maintain and restore health. The company focuses on signaling pathways that govern the proliferation and differentiation of cells. These same pathways control maintenance, repair, and regeneration of tissues and organs from infancy through old age. This approach has created an approved product for bone regeneration and enables Curis to build a portfolio of product candidates in neurology, kidney disease, and cancer.
keywords:Biotechnology
$69M
Total Funding
184
Number of Employees
$15M
Revenue (est)
-16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Curis News
The list of biotechs under clinical hold keeps getting longer. Curis is the latest company to join the list, with the FDA slapping a partial hold on a phase...
The open-label Phase 1/2 clinical trial of the Curis drug is a dose-escalation study enrolling patients with acute myeloid leukemia (AML) or...
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into...
LEXINGTON, Mass., Oct. 7, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced two poster presentations with new preclinical data for CA-4948, a first-in-class small molecule IR ...
LEXINGTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2021. "In the second quarter of 2021 ...
Other Companies in Lexington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $58.7M | 184 | 5% | N/A |
#2 | $62.1M | 185 | 29% | N/A |
#3 | $15M | 185 | 0% | N/A |
#4 | $75M | 185 | -3% | N/A |
#5 | $43M | 186 | 9% | N/A |